Intrinsically Disordered Regions: Why They Break Your Protein Pipeline

Your protein expresses well. It purifies to apparent homogeneity—a single peak on size exclusion, a clean band on SDS-PAGE. You set up 2,000 crystallization conditions. Nothing. Not a single crystal. You switch to cryo-EM. The 2D classes are fuzzy, the 3D reconstruction looks like a blob, and the resolution stalls at 8 Å. Your protein is doing everything right—except it won't give you a structure. Then you look at the AlphaFold model. A 130-residue stretch at the C-terminus is orange and red—pLDDT below 40. You've been dragging an intrinsically disordered tail through your entire pipeline.

Intrinsically disordered regions aren't "unstructured noise." They're active saboteurs of standard structural biology workflows, and ignoring them is one of the most expensive mistakes in protein science.

Key Takeaways

• ~30–40% of eukaryotic proteins contain long disordered regions (>30 residues), making this an extremely common problem

• IDRs break every step of the pipeline: expression (protease-sensitive), purification (anomalous SEC), crystallization (heterogeneity), cryo-EM (flexibility), assays (aggregation)

• AlphaFold pLDDT < 50 is a reliable disorder predictor, often outperforming dedicated tools—check it before you clone

• Removing IDRs increases crystallization success ~3x, but boundary design requires care to avoid cutting into structured regions

• Some experiments NEED the disorder: phase separation, IDP-binding interactions, and regulatory studies require intact disordered regions

How Common Are Intrinsically Disordered Regions?

The Numbers

Disorder is not a rare edge case. It's a defining feature of eukaryotic proteomes:

• ~30–40% of eukaryotic proteins contain disordered regions longer than 30 residues (Dunker et al., 2001)

• ~25% of eukaryotic proteins are predicted to be entirely disordered (>90% of residues in disorder)

• ~10% of bacterial proteins contain long disordered regions (much less common in prokaryotes)

• Ward et al. (2004) found that disorder length and frequency increase with organism complexity

By protein class:

If you work with eukaryotic signaling or regulatory proteins, you will encounter disorder. It's a question of when, not if.

What Are IDRs, Biologically?

Not Broken—Functional

The old view was that disorder meant "unfolded and nonfunctional." This is wrong. IDRs are often the most functionally important parts of a protein (Wright & Dyson, 2015):

Functional roles of disorder:

• Molecular recognition: Disordered regions mediate many protein-protein interactions. They fold upon binding ("coupled folding and binding"), enabling specificity with moderate affinity.

• Post-translational modification: PTM sites are overwhelmingly located in disordered regions. Disorder provides accessibility to kinases, acetyltransferases, and other modifying enzymes.

• Regulation: Disordered linkers and tails often contain regulatory motifs (degrons, nuclear localization signals, phospho-switches).

• Phase separation: IDRs drive liquid-liquid phase separation (LLPS), forming membraneless organelles like stress granules and P-bodies (Banani et al., 2017).

• Entropic effects: Disordered tethers can modulate effective local concentration of interacting domains.

The key insight: Disorder is evolutionarily conserved. If a region has been disordered across 500 million years of evolution, it's disordered for a reason.

AlphaFold and Disorder Detection

pLDDT as a Disorder Predictor

One of AlphaFold's most practically useful (and unintended) outputs is disorder prediction. Low pLDDT scores correlate strongly with intrinsic disorder:

• Ruff & Pappu (2021) demonstrated that AlphaFold consistently assigns pLDDT < 50 to experimentally validated disordered regions

• Wilson et al. (2022) systematically compared AlphaFold pLDDT against dedicated disorder predictors (IUPred2, PONDR-VSL2, ESpritz) and found comparable or superior performance for long disordered regions

• AlphaFold effectively provides a free, state-of-the-art disorder prediction for every model it generates

Practical thresholds:

Beyond pLDDT: Dedicated Disorder Predictors

Best practice: Use AlphaFold pLDDT as your primary screen. If a region is pLDDT < 50 across >20 residues, it's disordered—you don't need a second opinion. For ambiguous regions (pLDDT 50–70), cross-check with IUPred3 or PONDR.

How IDRs Break Each Pipeline Step

Expression: The Protease Magnet

Disordered regions are highly susceptible to proteolysis:

• E. coli proteases (Lon, ClpP, OmpT, DegP) preferentially target unstructured regions

• Extended, flexible sequences are recognized as "misfolded" by the quality control machinery

• Result: degradation during expression, truncated products, heterogeneous bands on SDS-PAGE

Signs your protein is being degraded at IDRs:

• Multiple bands on SDS-PAGE, all smaller than expected

• Bands decrease in size over time (ladder pattern)

• Protease inhibitors during lysis improve yield dramatically

Mitigation strategies:

• Express at 15–18°C (reduces protease activity)

• Use protease-deficient strains (BL21 ΔompT, Δlon)

• Add protease inhibitors to all buffers

• Remove the disordered region (best long-term solution)

Purification: The SEC Lie

Disordered proteins behave anomalously on size exclusion chromatography:

• Apparent molecular weight is inflated by 1.5–3x because IDRs adopt extended conformations

• A 50 kDa protein with a 100-residue IDR may elute at an apparent MW of 100–150 kDa

• You think you have an oligomer. You actually have a monomer with a floppy tail.

Additional purification problems:

• IDRs co-purify with chaperones (DnaK, GroEL) that bind to exposed hydrophobic stretches

• Disordered regions can interact nonspecifically with chromatography matrices

• Concentration of proteins with IDRs often triggers aggregation (increased local concentration of aggregation-prone sequences)

The fix:

• Use SEC-MALS (multi-angle light scattering) to get true molecular weight, not apparent

• Native mass spectrometry as an orthogonal check

• If chaperone contamination is persistent, add ATP + MgCl₂ to wash buffers to release DnaK

Crystallization: The Heterogeneity Killer

This is where IDRs do the most damage. Crystallization requires:

1. Conformational homogeneity

2. Defined surface features for crystal contacts

3. Rigid molecules that can pack into a lattice

IDRs violate all three requirements.

The numbers are stark:

• Analysis of structural genomics projects shows that removing predicted disordered regions increases crystallization success from ~20% to ~50–60%

• Proteins with >20% predicted disorder crystallize at roughly one-third the rate of fully ordered proteins

• Many crystallization "failures" are actually disorder problems disguised as optimization problems

Why 2,000 conditions don't help:
No crystallization condition can force a genuinely disordered region into a lattice. You can screen 10,000 conditions—if conformational heterogeneity is the problem, none will work.

The solution: Remove the disordered region. A well-designed truncation is worth more than 10,000 crystallization conditions.

Cryo-EM: The Resolution Ceiling

Cryo-EM is more tolerant of disorder than crystallography, but IDRs still cause problems:

• Flexible regions blur out during averaging—they're present in the particles but invisible in the map

• Conformational heterogeneity reduces the number of particles in each 3D class, lowering resolution

• Preferred orientation can be worsened by floppy domains that interact with the air-water interface

• Overall resolution is dragged down by flexible portions: a 2.5 Å core might be reported as 4 Å overall because the disordered tails are at 10+ Å

When disorder is acceptable in cryo-EM:

• If the disordered region is small relative to the structured core

• If you only need the structure of the ordered portion

• If the disorder is at a terminus (can be masked during refinement)

When disorder kills the experiment:

• Disordered linker between two domains of interest (flexible arrangement)

• Large IDR that dominates the mass of the particle

• Disorder at the periphery causing preferred orientation via surface interactions

Assay Development: The Nonspecific Binder

IDRs cause problems in biochemical and biophysical assays:

• Surface plasmon resonance (SPR): Disordered regions stick nonspecifically to sensor chips, creating false positives

• Isothermal titration calorimetry (ITC): Conformational heterogeneity creates complex thermodynamic signatures

• Activity assays: IDRs can aggregate during the assay, causing time-dependent artifacts

• Pull-downs: Disordered regions bind nonspecifically to beads, resins, and other proteins

The Construct Design Solution

How to Identify Where to Cut

Method 1: AlphaFold pLDDT profile

• Plot pLDDT per residue

• Domain boundaries are where pLDDT drops from >70 to <50

• Cut at the transition point, leaving 3–5 residues of "buffer"

Method 2: PAE domain blocks

• The PAE matrix shows rigid domains as blue blocks

• The edges of these blocks define domain boundaries

• Red/yellow between blocks = flexible linkers (good cutting points)

Method 3: Limited proteolysis

• Digest your full-length protein with low concentrations of trypsin or chymotrypsin

• Analyze fragments by mass spectrometry

• Stable fragments correspond to folded domains; cut sites map to disordered linkers

• This is the gold standard but requires purified protein first

Method 4: Secondary structure prediction

• Cut between the last secondary structure element of one domain and the first of the next

• Avoid cutting in the middle of helices or strands

Where Exactly to Cut

Common Construct Design Mistakes

Mistake 1: Cutting too deep into the structured region

• If you cut 10 residues into the folded domain to "make sure" you removed all disorder, you may destabilize the fold

• The last helix or strand before the disordered region is often critical for domain stability

Mistake 2: Cutting in the middle of a disordered linker between two interacting domains

• If two domains interact through the linker, cutting it may disrupt the interaction

• Check inter-domain PAE: if it's low (<10 Å), the domains have a fixed relationship and the linker matters

Mistake 3: Not testing multiple construct boundaries

• Always design 2–3 constructs with slightly different boundaries (+5/–5 residues)

• The optimal boundary is often not obvious from prediction alone

Mistake 4: Forgetting that the first Met will be processed

• E. coli removes the initiator Met when the second residue is small (Ala, Cys, Gly, Pro, Ser, Thr, Val)

• If your new N-terminal residue after truncation has a bulky side chain, Met will be retained

• This is usually harmless but can affect crystallization

When You NEED the Disorder

Phase Separation Studies

Liquid-liquid phase separation (LLPS) is driven by multivalent, weak interactions in disordered regions. If you're studying:

• Stress granule formation

• Nucleolar assembly

• Transcriptional condensates

You need the IDRs intact. Removing them removes the biology.

IDP Binding Interactions

Many protein-protein interactions are mediated by disordered motifs that fold upon binding:

• p53 transactivation domain binding to MDM2

• CREB KID domain binding to CBP KIX domain

• Disordered tails of histones binding to chromatin remodelers

For these studies, you need the disordered region—it IS the binding interface.

Regulatory and Signaling Studies

Post-translational modifications in disordered regions often serve as molecular switches:

• Phosphorylation of disordered activation loops

• Ubiquitination of disordered degrons

• SUMOylation of disordered regulatory regions

Removing the IDR removes the regulation.

Strategies for Working WITH Disorder

When you can't remove the disordered region, use strategies to manage it:

Strategy 1: Binding Partners That Stabilize

Some disordered regions become ordered upon binding their natural partner:

• Co-express or co-purify with the binding partner

• The bound complex may be suitable for crystallization or cryo-EM

• Example: p27Kip1 is disordered alone but folds when bound to Cdk2-Cyclin A (Russo et al., 1996)

Strategy 2: Cross-Linking for Structural Studies

Chemical cross-linking captures transient contacts in disordered regions:

• XL-MS (cross-linking mass spectrometry) provides distance restraints

• Integrative structural biology combines XL-MS with SAXS and computational modeling

• This approach works well for proteins with extensive disorder

Strategy 3: SAXS for Ensemble Characterization

Small-angle X-ray scattering doesn't require a single conformation:

• Provides overall shape and dimensions

• Can distinguish compact vs extended conformations

• Ensemble fitting methods (EOM, EROS) model the distribution of conformations

• Ideal for characterizing the overall behavior of disordered regions

Strategy 4: NMR for Residue-Level Dynamics

NMR is the method of choice for studying disordered regions at atomic resolution:

• Chemical shifts report on secondary structure propensity

• Relaxation measurements quantify dynamics on multiple timescales

• PRE (paramagnetic relaxation enhancement) reports on transient long-range contacts

• Size limit: works best for isolated disordered domains (<25 kDa)

Strategy 5: Small Molecules or Peptides That Stabilize

Some disordered regions can be stabilized by:

• Substrate analogs or cofactors

• Stabilizing small molecules identified by fragment screening

• Peptides that mimic binding partners

Classic Examples

p53: The Most Studied Disordered Protein

• Full-length p53 (393 residues) is ~30% disordered

• The N-terminal transactivation domain (residues 1–61) is fully disordered

• The C-terminal regulatory domain (residues 364–393) is disordered

• Only the DNA-binding domain (residues 94–292) has a stable fold

• Thousands of crystallization attempts on full-length p53 have failed

• All p53 crystal structures are of isolated domains or domain complexes

Tau: Natively Unfolded, Pathologically Structured

• Tau (441 residues in the longest isoform) is entirely disordered in its native state

• No crystal structure of full-length monomeric tau exists

• Upon aggregation in Alzheimer's disease, portions of tau form ordered amyloid fibrils

• Cryo-EM structures of tau filaments reveal ordered cores surrounded by disordered "fuzzy coats"

• Studying tau requires IDR-tolerant methods (NMR, SAXS, single-molecule techniques)

BRCA1: The Construct Design Success Story

• BRCA1 (1,863 residues) is largely disordered

• The BRCT domains (residues ~1,646–1,859) are the only well-structured region

• Crystal structures of BRCA1 BRCT were obtained only after decades of construct optimization

• Success required identifying exact domain boundaries and removing all disordered flanking regions

• The difference between a construct that crystallizes and one that doesn't can be as few as 5 residues

The Bottom Line

The most important habit: Check the AlphaFold model BEFORE you clone. A 60-second look at the pLDDT profile can save you 6 months of failed crystallization trials.

Identifying and Designing Around Disorder with Orbion

Orbion provides multiple tools for handling disorder before it becomes a problem. AstraUNFOLD predicts per-residue disorder probability and amyloidogenicity directly from sequence, flagging regions likely to cause problems in expression, purification, and structural studies. The PAE Insight Engine automatically identifies domain boundaries and hinge regions from AlphaFold confidence data, so you can see exactly where rigid domains end and flexible linkers begin.

The Construct Design module translates these predictions into action: select expression construct boundaries based on predicted disorder-to-structure transitions, add appropriate tags and fusion partners, and generate codon-optimized sequences—all within the same workflow. Combined with AlphaFold2 pLDDT visualization in the 3D viewer, you can go from "my protein has disorder" to "here's the construct that will work" before ordering a single primer.

References

1. Dunker AK, et al. (2001). Intrinsically disordered protein. Journal of Molecular Graphics and Modelling, 19(1):26-59. PMC2373533

2. Ward JJ, et al. (2004). Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. Journal of Molecular Biology, 337(3):635-645. Link

3. Wright PE & Dyson HJ. (2015). Intrinsically disordered proteins in cellular signalling and regulation. Nature Reviews Molecular Cell Biology, 16:18-29. Link

4. Banani SF, et al. (2017). Biomolecular condensates: organizers of cellular biochemistry. Nature Reviews Molecular Cell Biology, 18:285-298. Link

5. Ruff KM & Pappu RV. (2021). AlphaFold and implications for intrinsically disordered proteins. Journal of Molecular Biology, 433(20):167208. Link

6. Wilson CJ, et al. (2022). AlphaFold2 and disorder: Are predicted confidence scores a good substitute for disorder predictors? Proteins, 90(12):2109-2118. Link

7. Derewenda ZS. (2004). The use of recombinant methods and molecular engineering in protein crystallization. Methods, 34(3):354-363. PMC2238902

8. Russo AA, et al. (1996). Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature, 382:461-464. Link

9. Fitzpatrick AWP, et al. (2017). Cryo-EM structures of tau filaments from Alzheimer's disease. Nature, 547:185-190. Link

10. Williams RS, et al. (2001). Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nature Structural Biology, 8:838-842. PMC2737721

11. Oldfield CJ & Dunker AK. (2014). Intrinsically disordered proteins and intrinsically disordered protein regions. Annual Review of Biochemistry, 83:553-584. Link

12. Tompa P. (2012). Intrinsically disordered proteins: a 10-year recap. Trends in Biochemical Sciences, 37(12):509-516. Link